Last updated: February 15, 2026
What is the current market status for NDC 23155-0149?
The National Drug Code (NDC) 23155-0149 corresponds to Tafasitamab (marketed as Monjuvi), a monoclonal antibody indicated for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Approved by the FDA in 2020, it primarily targets adult patients who have shown inadequate response or are ineligible for stem cell transplant or CAR T-cell therapy.
The drug’s market uptake remains constrained due to factors including competitive landscape, pricing concerns, and treatment guidelines. Monjuvi's sales figures, though growing, are still in the early growth phase, with revenues estimated around $100 million in 2022, according to IQVIA data.
How is the market for tafasitamab positioned within its therapeutic class?
Tafasitamab functions in the B-cell lymphoma space, competing primarily against CAR T-cell therapies (e.g., axi-cel, tisa-cel) and other monoclonal antibodies like rituximab, pola, and loncastuximab. The treatment landscape exhibits high competition with established therapies, influencing market penetration and pricing strategies.
What factors influence the drug’s price trajectory?
Price projections hinge upon several elements:
-
Pricing benchmarks: The list price for tafasitamab is approximately $13,000 per dose (based on a typical regimen of 12 doses), aligning with other monoclonal antibodies. The total course costs around $150,000.
-
Rebate and discount trends: Actual net prices are lower after rebates, insurance negotiations, and patient assistance programs.
-
Market penetration: Increased adoption due to additional approvals (e.g., for earlier lines of therapy) could raise revenue.
-
Competitor pricing: CAR T therapies are priced at approximately $373,000 upfront, but with differing administration and durability factors. Their high costs create pricing pressure on monoclonal antibodies.
-
Insurance reimbursement policies: Reimbursement cuts or restrictions could pressure net revenue and pricing.
Given these factors, the drug might see a moderate price increase of 2-4% annually over the next five years if market penetration improves, with no significant downward pressure unless new competition or generic versions emerge.
What are the projections for revenue and price growth?
| Year |
Estimated Market Share |
Projected Revenue (USD Millions) |
Price per Dose (USD) |
Notes |
| 2022 |
10% |
100 |
$13,000 |
Starting point |
| 2023 |
12% |
130 |
$13,250 |
Slight growth |
| 2024 |
15% |
180 |
$13,500 |
Increased uptake |
| 2025 |
20% |
250 |
$13,750 |
Market expansion |
| 2026 |
25% |
320 |
$14,000 |
Additional approvals |
Note: These estimates incorporate assumed increases in market share, slight price growth, and competitive dynamics.
How do external factors impact pricing?
- Regulatory approvals: Additional indications could expand market size, elevating prices.
- Reimbursement policies: Stricter reimbursement could suppress net sales.
- Emerging competitors: New therapies under development may pressure pricing.
- Cost-of-goods and manufacturing: Advances reducing production costs could allow margin improvements without raising prices.
Summary of key market hows and whys:
- The drugs' current list price remains high but is comparable with similar monoclonal antibody therapies.
- Price increases are limited by insurance negotiations and payer policies.
- Market expansion depends on label expansion, clinical acceptance, and competition.
- Revenue projections suggest steady growth aligned with increased adoption and market share.
What are the strategic implications?
Investors and manufacturers should monitor:
- Pending clinical trial results for combination therapies or indications.
- Payer reimbursement strategies.
- Competitive developments in cellular therapies.
- Policy shifts affecting monoclonal antibody pricing.
Key Takeaways
- NDC 23155-0149 (tafiasitamab) is in a growth phase with revenue estimated near $100 million in 2022, driven by its targeted treatment for DLBCL.
- Price per dose remains around $13,000, with modest annual growth expected.
- Sales growth depends on expanded indications, market share gains, and competitive landscape adjustments.
- External factors like reimbursement policies and new entrants will significantly influence future pricing.
FAQs
1. What is the expected timeline for price increases for tafasitamab?
Price increases are projected at 2-4% annually over the next five years, contingent upon market acceptance and competitive pressures.
2. How does tafasitamab’s pricing compare to CAR T therapies?
Tafasitamab’s per-treatment cost is about $150,000, significantly lower than CAR T therapies priced around $373,000, but CAR T offers potential durability benefits which influence value.
3. Are there upcoming regulatory decisions affecting tafasitamab?
Possible extensions of indications or combination approvals could expand the market, but no major regulatory milestones are imminent at this time.
4. How do reimbursement policies affect price projections?
Tighter reimbursement criteria or coverage restrictions could suppress net revenue, limiting price growth. Continuous monitoring of payer policies is necessary.
5. What are the main competitive threats to tafasitamab?
Emerging CAR T-cell therapies, biosimilars, and new monoclonal antibodies targeting similar pathways could intensify competition, affecting market share and pricing.
Sources:
[1] IQVIA, "Pharmaceutical Market Trends," 2022.
[2] FDA, "Tafasitamab (Monjuvi) Approval Details," 2020.
[3] EvaluatePharma, "Monoclonal antibody market analysis," 2023.
